<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03662711</url>
  </required_header>
  <id_info>
    <org_study_id>AIFA-ICSLIFE-001</org_study_id>
    <nct_id>NCT03662711</nct_id>
  </id_info>
  <brief_title>Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Comparison of 1-year Treatment With Inhaled Long Acting Bronchodilators (LABD) Plus Inhaled Glucocorticosteroids (ICS) Versus LABD Without ICS on Re-hospitalizations and/or Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (COPD) Recently Hospitalized Because of an Acute Exacerbation of COPD (ICS-Life Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi di Ferrara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi di Ferrara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a phase IV, open label, multicenter, randomized pragmatic study in frail elderly
      patients with COPD. Participants will be treated with either inhaled LABD alone or LABD
      combined with inhaled glucocorticosteroids. The main aim of the study is to assess whether,
      in elderly patients with COPD and one or more cardiac comorbidities (heart failure, and/or
      ischemic heart disease, and/or atrial fibrillation) recently hospitalized because of an acute
      exacerbation of COPD, 12 months treatment with LABD(s)+ICS can increase the time to first
      re-hospitalization (all cause) and/or death for any cause when compared with LABD(s) alone.
      Patients will be followed-up for 3 months after completion of the 12 month treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic obstructive pulmonary disease occurs mainly in the elderly and has important
      comorbidities, particularly cardiovascular, which increase its severity. Chronic obstructive
      pulmonary disease affects 5% of people globally, increasing to 10% in the elderly. According
      to data from the World Health Organisation (WHO), there were 384 million cases of COPD in
      2010, with a global prevalence of 12% (www.who.int). Deaths due to COPD are 3 million/year
      globally (GOLD 2018) and &gt;20,000/year in Italy.

      The investigator speculated that multimorbid elderly COPD patients recently hospitalized due
      to an acute exacerbation of COPD (AECOPD) and who have concomitant cardiovascular disease may
      have fewer re-hospitalizations and increased survival in the following year if treated with
      LABD+ICS rather than with LABD alone.

      The aim of this study is to examine the efficacy and safety of currently recommended and
      prescribed inhalation therapies to elderly, frail and multimorbid COPD patients with a recent
      hospitalization due to an AECOPD. The study involves a group of patients who have never
      before been selected for a clinical trial and who represent the 5th most common cause of
      hospitalization and the 3rd most common cause of death in Italy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite event of the first time to first re-hospitalization and/or death (all cause)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of moderate/severe COPD exacerbations in the two patient groups</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of re-hospitalizations and deaths (all cause) in the two patient groups</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) variation measured as change in COPD Assessment Test (CAT) between the two patient groups</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL variation measured using modified Medical Research Council (mMRC) dyspnoea scale between the two patient groups</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pneumonia events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of acute cardiac events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cardiovascular events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in forced expiratory volume at one second (FEV1) from baseline to the end of treatment period</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in forced vital capacity (FVC) from baseline to the end of treatment period</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1032</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Long-acting beta-agonist (LABA) or LABA/LAMA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>long-acting bronchodilator agents (LABD, LAMA or LABA/LAMA) but no inhaled steroids plus usual care for comorbidities</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long-acting muscarinic antagonist (LAMA) and/or LABA plus ICS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bronchodilator agents LAMA and/or LABA with inhaled steroids plus usual care for comorbidities</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Fluticasone furoate/vilanterol</description>
    <arm_group_label>Long-acting muscarinic antagonist (LAMA) and/or LABA plus ICS</arm_group_label>
    <other_name>Revinty Ellipta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Tiotropium</description>
    <arm_group_label>Long-acting beta-agonist (LABA) or LABA/LAMA</arm_group_label>
    <other_name>Spiriva Respimat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Indacaterol</description>
    <arm_group_label>Long-acting beta-agonist (LABA) or LABA/LAMA</arm_group_label>
    <other_name>Onbreez Brezhaler 150</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Umeclidinium/vilanterol</description>
    <arm_group_label>Long-acting beta-agonist (LABA) or LABA/LAMA</arm_group_label>
    <other_name>Laventair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Fluticasone propionate/salmeterol</description>
    <arm_group_label>Long-acting muscarinic antagonist (LAMA) and/or LABA plus ICS</arm_group_label>
    <other_name>Aliflus Diskus 50/500</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Beclometasone dipropionate/formoterol</description>
    <arm_group_label>Long-acting muscarinic antagonist (LAMA) and/or LABA plus ICS</arm_group_label>
    <other_name>Alabaster</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Budesonide formoterol</description>
    <arm_group_label>Long-acting muscarinic antagonist (LAMA) and/or LABA plus ICS</arm_group_label>
    <other_name>Fobuler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Glycopyrronium</description>
    <arm_group_label>Long-acting beta-agonist (LABA) or LABA/LAMA</arm_group_label>
    <other_name>Tovanor Breezhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Aclidinium</description>
    <arm_group_label>Long-acting beta-agonist (LABA) or LABA/LAMA</arm_group_label>
    <other_name>Bretaris Genuair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Umeclidinium</description>
    <arm_group_label>Long-acting beta-agonist (LABA) or LABA/LAMA</arm_group_label>
    <other_name>Incruse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Formoterol</description>
    <arm_group_label>Long-acting beta-agonist (LABA) or LABA/LAMA</arm_group_label>
    <other_name>Levovent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Indacaterol glycopyrronium</description>
    <arm_group_label>Long-acting beta-agonist (LABA) or LABA/LAMA</arm_group_label>
    <other_name>Ultibro Breezhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Salmeterol</description>
    <arm_group_label>Long-acting beta-agonist (LABA) or LABA/LAMA</arm_group_label>
    <other_name>Serevent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Tiotropium olodaterol</description>
    <arm_group_label>Long-acting beta-agonist (LABA) or LABA/LAMA</arm_group_label>
    <other_name>Spiolto Respimat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Aclidinium/formoterol</description>
    <arm_group_label>Long-acting beta-agonist (LABA) or LABA/LAMA</arm_group_label>
    <other_name>Duaklir Genuair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Olodaterol</description>
    <arm_group_label>Long-acting beta-agonist (LABA) or LABA/LAMA</arm_group_label>
    <other_name>Striverdi Respimat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Formoterol/glycopyrronium bromide/beclometasone dipropionate</description>
    <arm_group_label>Long-acting muscarinic antagonist (LAMA) and/or LABA plus ICS</arm_group_label>
    <other_name>Trimbow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Agents</intervention_name>
    <description>Fluticasone furoate/umeclidinium bromide/vilanterol</description>
    <arm_group_label>Long-acting muscarinic antagonist (LAMA) and/or LABA plus ICS</arm_group_label>
    <other_name>Elebrato Ellipta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant must be older than 60 years of age, at the time of signing the informed
             consent.

          2. Recently (within 6 months) discharged from hospital with a diagnosis of acute
             exacerbation of COPD (usually coded as Diagnosis Related Group (DRG) 087 or 088).

          3. Participants with a clinical diagnosis of COPD (i.e. previous diagnosis of COPD and/or
             treatment with short acting bronchodilators (SABD), LABD or LABD+ICS

          4. Spirometry confirmed diagnosis of COPD, post-bronchodilator (30 minutes after 400 μg
             salbutamol) FEV1/FVC ratio &lt;0.7. The diagnostic spirometry test can have been
             performed up to three years prior to randomization, or if never performed before,
             should be performed not earlier than 4 weeks since last exacerbation

          5. Smokers or ex-smokers with a smoking history of &gt;10 pack years (a pack year is defined
             as 20 cigarettes smoked every day for a year)

          6. Clinical diagnosis documented in the patient's medical records of one or more major
             chronic cardiac disease (heart failure, ischemic heart disease or atrial
             fibrillation).

          7. Currently receiving at least one of the specified treatments (either alone or in
             combination, see Appendix 10.5) for heart failure, ischemic heart disease or atrial
             fibrillation.

          8. Participant must be willing and able to perform pulmonary function tests

          9. Male or female. Contraception is not considered necessary in this cohort of elderly (&gt;
             65 years) patients receiving treatment with commercially available licensed products.

         10. Capable of giving signed informed consent as described in Appendix 1 which includes
             compliance with the requirements and restrictions listed in the informed consent form
             (ICF) and in this protocol.

        Exclusion Criteria:

          1. Patients with a primary discharge diagnosis of DRG 087 or DRG 088 but clearly judged
             by the clinical investigator to be due to other causes, i.e. patients presenting to
             the hospital with symptoms of AECOPD but due mainly to other conditions (pulmonary
             embolism, pneumonia, pneumothorax, anemia, acute kidney failure, decompensated heart
             failure, acute ischemic heart disease, new onset atrial fibrillation, stroke, etc.)

          2. Patients who required invasive mechanical ventilation during hospitalization

          3. Patients with Asthma as primary and principal diagnosis

          4. Patients with severe cardiovascular (CV) disease who in the opinion of the
             investigator are unlikely to survive the 15 month study period

          5. Patients considered unable to comply with the study procedures and follow-up in the
             opinion of the investigator (eg, evidence of alcohol or drug abuse, psychiatric
             disorder, physical disability, social or geographical obstacles)

          6. Patients in whom spirometry is contraindicated (eg, hemoptysis, detached retina,
             active tuberculosis, last trimester of pregnancy)

          7. Patients with other mechanical or overt causes of respiratory symptoms, particularly
             dyspnea (such as pneumothorax, chest wall trauma, lung fibrosis, lung cancer, anemia,
             severe obesity (BMI &gt;40) or cachexia (BMI &lt;18))

          8. Patients with any major disease which in the opinion of the investigator would prevent
             study participation, such as dementia, end-stage disease, cachexia, chronically
             bedridden patient and life expectancy &lt;15 months.

          9. Participation in any other interventional study within the last 3 months or concurrent
             participation in an observational clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alberto Papi, MD</last_name>
    <phone>+039 0532 210420</phone>
    <email>ppa@unife.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabio Gambini</last_name>
    <phone>+039 045 8202666</phone>
    <email>icslife@crosnt.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Policlinico di Bari, U.O.C. Malattie dell'Apparato Respiratorio Universitaria</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanna Elisiana Carpagnano, MD</last_name>
      <email>elisiana.carpagnano@uniba.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituti Clinici Scientifici Maugeri S.p.A - SB, Pneumologia Riabilitativa</name>
      <address>
        <city>Telese Terme</city>
        <state>Benevento</state>
        <zip>82037</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Maniscalco, MD</last_name>
      <email>mauro.maniscalco@icsmaugeri.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento Di Scienze Mediche e Chirurgiche- Università Magna Grecia</name>
      <address>
        <city>Catanzaro</city>
        <state>Calabria</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Girolamo Pelaia, MD</last_name>
      <email>pelaia@unicz.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni di Dio, UOC Medicina Interna</name>
      <address>
        <city>Crotone</city>
        <state>Calabria</state>
        <zip>88900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppina Schipani, MD</last_name>
      <email>giusyschipani@yahoo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Jazzolino&quot; ASP, UOC Medicina Interna</name>
      <address>
        <city>Vibo Valentia</city>
        <state>Calabria</state>
        <zip>89900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerio Cosimo Manno, MD</last_name>
      <email>valerio.manno@tin.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale civile di Battipaglia, Medicina, Servizio di Allergologia e Immunologia Clinica</name>
      <address>
        <city>Battipaglia</city>
        <state>Campania</state>
        <zip>84091</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Patella, MD</last_name>
      <email>pobattipaglia.allerg@aslsalerno.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera dei Colli - Ospedale Monaldi</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Molino, MD</last_name>
      <email>antonio.molino@ospedalideicolli.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Modena e Reggio Emilia, Clinica Malattie dell'apparato Respiratorio</name>
      <address>
        <city>Modena</city>
        <state>Emilia Romagna</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Clini, MD</last_name>
      <email>enrico.clini@unimore.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-universitaria di Parma, Clinica pneumologica</name>
      <address>
        <city>Parma</city>
        <state>Emilia Romagna</state>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>AUSL - IRCCS di Reggio Emilia, Pneumologia</name>
      <address>
        <city>Reggio Emilia</city>
        <state>Emilia Romagna</state>
        <zip>42122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Facciolongo, MD</last_name>
      <email>nicolacosimo.facciolongo@ausl.re.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNIVERSITà DEGLI STUDI DI FERRARA, CLINICA DI MALATTIE DELL'APPARATO RESPIRATORIO</name>
      <address>
        <city>Ferrara</city>
        <state>FE</state>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Papi, MD</last_name>
      <phone>+390532210420</phone>
      <email>ppa@unife.it</email>
    </contact>
    <investigator>
      <last_name>Brunilda Marku, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giacomo Forini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marianna Padovani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Foggia, ospedale pneumologico D'Avanzo, unità operativa di malattie dell'apparato respiratorio</name>
      <address>
        <city>Foggia</city>
        <state>FG</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Pia Foschino, MD</last_name>
      <phone>+390881617832</phone>
      <email>mfoschino@qubisoft.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria degli Angeli - AAS5 Friuli Occidentale, Pneumologia</name>
      <address>
        <city>Pordenone</city>
        <state>Friuli Venezia Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Barbetta, MD</last_name>
      <email>carlo.barbetta@aas5.sanita.fvg.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico di Roma, Medicina Interna e Geriatria</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Antonello Incalzi, MD</last_name>
      <email>r.antonelli@unicampus.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università di Roma &quot;Tor Vergata&quot;, Dipartimento di Medicina dei Sistemi, Malattie dell'apparato respiratorio</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Rogliani, MD</last_name>
      <email>paola.rogliani@uniroma2.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASL2 Savonese, Ospedale S. Corona, Pneumologia</name>
      <address>
        <city>Pietra Ligure</city>
        <state>Liguria</state>
        <zip>17027</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manlio Milanese, MD</last_name>
      <email>m.milanese@asl2.liguria.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Paolo, Medicina 2 e cure Intermedie</name>
      <address>
        <city>Savona</city>
        <state>Liguria</state>
        <zip>17100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Gnerre, MD</last_name>
      <email>pgnerre@yahoo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabiano Di Marco, MD</last_name>
      <email>fabiano.dimarco@unimi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Figlie di San Camillo, Medicina Interna</name>
      <address>
        <city>Cremona</city>
        <state>Lombardia</state>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Marvisi, MD</last_name>
      <email>mmarvisi@alice.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Ovest Milanese - Ospedale civile di Legnano, Medicina interna</name>
      <address>
        <city>Legnano</city>
        <state>Lombardia</state>
        <zip>20025</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Ospedale Maggiore di Lodi</name>
      <address>
        <city>Lodi</city>
        <state>Lombardia</state>
        <zip>26900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Tursi, MD</last_name>
      <email>Francesco.Tursi@asst-lodi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Carlo Poma&quot;, Struttura Complessa Pneumologia e UTIR</name>
      <address>
        <city>Mantova</city>
        <state>Lombardia</state>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe De Donno, MD</last_name>
      <email>giuseppe.dedonno@asst-mantova.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;L. Sacco&quot; - Polo Universitario ASST Fatebenefratelli Sacco, Pneumologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierachille Santus, MD</last_name>
      <email>pierachille.santus@unimi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo, Pneumologia</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Corsico, MD</last_name>
      <email>corsico@unipv.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituti Clinici Scientifici Fondazione Maugeri, Pneumologia Riabilitativa</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piero Ceriana, MD</last_name>
      <email>piero.ceriana@icsmaugeri.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituti Clinici Scientifici maugeri, Pneumologia Riabilitativa</name>
      <address>
        <city>Tradate</city>
        <state>Lombardia</state>
        <zip>21049</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Spanevello, MD</last_name>
      <email>antonio.spanevello@icsmaugeri.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Ancona, Pneumologia</name>
      <address>
        <city>Torrette</city>
        <state>Marche</state>
        <zip>60030</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Gasparini, MD</last_name>
      <email>s.gasparini52@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Palermo, Ospedale &quot;V. Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <state>Pa</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Scichilone, MD, PHD</last_name>
      <phone>0916802652</phone>
      <email>n.scichilone@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Padova, dipartimento di Pneunmologia</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marina Saetta, MD</last_name>
      <phone>+390498213732</phone>
      <email>marina.saetta@unipd.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore, Medicina interna</name>
      <address>
        <city>Chieri</city>
        <state>Piemonte</state>
        <zip>10023</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale di Ceva, Medicina interna</name>
      <address>
        <city>San Bernardino</city>
        <state>Piemonte</state>
        <zip>12073</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile SS. Annunziata, Medicina interna</name>
      <address>
        <city>Savigliano</city>
        <state>Piemonte</state>
        <zip>12038</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Gulli, MD</last_name>
      <email>giovanni.gulli@aslcn1.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Ospedaliero di Varese - Ospedale di Circolo e Fondazione Macchi, Medicina interna</name>
      <address>
        <city>Varese</city>
        <state>Piemonte</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Dentali, MD</last_name>
      <email>fdentali@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituti Clinici Scientifici Maugeri, Pneumologia Riabilitativa</name>
      <address>
        <city>Veruno</city>
        <state>Piemonte</state>
        <zip>28010</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Balbi, MD</last_name>
      <email>bruno.balbi@icsmaugeri.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituti Clinici Scientifici Maugeri, Pneumologia Riabilitativa</name>
      <address>
        <city>Cassano Delle Murge</city>
        <state>Puglia</state>
        <zip>70020</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Aliani, MD</last_name>
      <email>maria.aliani@icsmaugeri.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria &quot;Policlinico Vittorio Emanuele&quot;, Pneumologia</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Crimi, MD</last_name>
      <email>dott.claudiacrimi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-universitaria Careggi, Medicina per la alta complessità Assistenziale 1</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Nozzoli, MD</last_name>
      <email>nozzolicarlo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-universitaria Careggi, Medicina per la alta complessità Assistenziale 2</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Corradi, MD</last_name>
      <email>francescocorradi72@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Siena, UOC Malattie respiratorie</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Bargagli, MD</last_name>
      <email>bargagli2@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Cattinara, unità operativa di pneumologia</name>
      <address>
        <city>Trieste</city>
        <state>TS</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Cà Foncello</name>
      <address>
        <city>Treviso</city>
        <state>Veneto</state>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Micaela Romagnoli, MD</last_name>
      <email>micaela.romagnoli@aulss2.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Monaldi, UOC Clinica Pneumologica</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Bianco, MD</last_name>
      <phone>0815453017</phone>
      <email>andrea.bianco@unicampania.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi di Ferrara</investigator_affiliation>
    <investigator_full_name>Alberto Papi, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>adult</keyword>
  <keyword>drug therapy</keyword>
  <keyword>combination</keyword>
  <keyword>bronchodilator agents</keyword>
  <keyword>male</keyword>
  <keyword>female</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchodilator Agents</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

